---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017922"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:19:14.862212+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma appoints Christopher Brooke as COO, effective Nov 14, 2022

## Summary
- Christopher Brooke previously served as EVP Rare Disease Development since April 2021.
- Brooke holds a 47.5% ownership interest in Rumpus, from which Aytu acquired enzastaurin license.
- Aytu paid $4.0M in milestones to Rumpus in fiscal 2022 ($2.6M cash + 2,188,940 shares).
- Brooke has over 20 years healthcare management experience at Johnson & Johnson, AstraZeneca, and AmerisourceBergen.

## SEC filing metadata
- accession: 0001558370-22-017922
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/0001558370-22-017922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/aytu-20221115x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017922
- JSON: https://secwatch.observer/filing/0001558370-22-017922.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017922.txt

## Key facts
- Executive change
  Christopher Brooke was appointed as Chief Operating Officer at AYTU BIOPHARMA, INC.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: Effective November 14, 2022, Aytu BioPharma, Inc. (the “Company”) appointed Christopher Brooke as Chief Operating Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/0001558370-22-017922-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.